Unterehmen auf Watchlist setzen
Reneo Pharmaceuticals
ISIN: US75974E1038
WKN: A3CMW7
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Reneo Pharmaceuticals · ISIN: US75974E1038 · Business Wire (ID: 20240829228753)
29 August 2024 07:39PM

RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM


Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Reneo Pharmaceuticals, Inc. (NasdaqGM: RPHM) (the “Company”) and OnKure, Inc. Upon completion of the proposed transaction, pre-merger Reneo shareholders are expected to own approximately 31% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Reneo shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-rphm/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contact

Kahn Swick & Foti, LLC
Managing Partner
Lewis S. Kahn
lewis.kahn@ksfcounsel.com
855-768-1857

This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2025
BusinessWire
Kontakt:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422